InvestSMART

Clarity Pharmaceuticals Ltd (ASX: CU6) - Announcements

Current share price for CU6 : $2.210 0.03 (1.34%)+

ASX company news and announcements for Clarity Pharmaceuticals Ltd (CU6) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Clarity Pharmaceuticals Ltd (CU6) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Clarity Pharmaceuticals Ltd (CU6), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Clarity Pharmaceuticals Ltd (CU6)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$825 Application for quotation of securities - CU6 29 Jun 2022 4:39PM $0.525 $2.210 risen by 320.95%
$825 Leading Australian cancer expert joins Clarity SAB 29 Jun 2022 10:12AM $0.500 $2.210 risen by 342%
$825 Change of Director's Interest Notice O'Bryan-Tear 23 Jun 2022 8:59AM $0.395 $2.210 risen by 459.49%
$825 Application for quotation of securities - CU6 22 Jun 2022 2:16PM $0.400 $2.210 risen by 452.50%
$825 Release of Securities from Escrow 20 Jun 2022 9:24AM $0.435 $2.210 risen by 408.05%
$825 Governance & Trading Policy Update 9 Jun 2022 8:32AM $0.460 $2.210 risen by 380.43%
$825 IND Approval by US FDA for Phase II SAR-Bombesin trial 6 Jun 2022 9:31AM $0.475 $2.210 risen by 365.26%
$825 Notification regarding unquoted securities - CU6 1 Jun 2022 4:53PM $0.490 $2.210 risen by 351.02%
$825 Change of Director's Interest Notice - Thomas Ramdahl 1 Jun 2022 9:21AM $0.490 $2.210 risen by 351.02%
$825 Change of Director's Interest Notice - Rob Thomas 31 May 2022 11:20AM $0.490 $2.210 risen by 351.02%
$825 Clarity adds innovative nanobody IP 31 May 2022 10:04AM $0.485 $2.210 risen by 355.67%
$825 Presentation Jefferies Biotech Summit 27 May 2022 10:00AM $0.450 $2.210 risen by 391.11%
$825 Dr Neal Shore joins Clarity's CAB 26 May 2022 9:36AM $0.460 $2.210 risen by 380.43%
$825 Clarity confirms no supply issues to its clinical trials 10 May 2022 3:01PM $0.450 $2.210 risen by 391.11%
$825 Quarterly Activities/Appendix 4C Cash Flow Report 29 Apr 2022 6:24PM $0.520 $2.210 risen by 325%
$825 Cleansing Notice 21 Apr 2022 4:42PM $0.595 $2.210 risen by 271.43%
$825 Application for quotation of securities - CU6 21 Apr 2022 3:17PM $0.580 $2.210 risen by 281.03%
$825 First patient treated in the prostate cancer imaging trial 21 Apr 2022 9:47AM $0.570 $2.210 risen by 287.72%
$825 Application for quotation of securities - CU6 14 Apr 2022 3:53PM $0.573 $2.210 risen by 286.03%
$825 Notification of cessation of securities - CU6 14 Apr 2022 8:18AM $0.575 $2.210 risen by 284.35%
$825 Dr Andrei Iagaru joins Clarity Scientific Advisory Board 5 Apr 2022 9:46AM $0.630 $2.210 risen by 250.79%
$825 Appointment of CFO 4 Apr 2022 4:04PM $0.630 $2.210 risen by 250.79%
$825 COBRA trial in prostate cancer opens for recruitment 28 Mar 2022 9:53AM $0.590 $2.210 risen by 274.58%
$825 New clinical trial collaboration in prostate cancer 24 Mar 2022 9:00AM $0.575 $2.210 risen by 284.35%
$825 Clarity - Investor Presentation 03-03-2022 3 Mar 2022 9:38AM $0.640 $2.210 risen by 245.31%

426 - 450 of 511 results

Page 18 of 21

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.